Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
0.650
-0.005 (-0.76%)
At close: Dec 5, 2025, 4:00 PM EST
0.659
+0.009 (1.38%)
After-hours: Dec 5, 2025, 7:59 PM EST
Plus Therapeutics Stock Forecast
PSTV's stock price has decreased by -51.13% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Plus Therapeutics stock have an average target of 7.25, with a low estimate of 2.00 and a high estimate of 19. The average target predicts an increase of 1,015.38% from the current stock price of 0.65.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Plus Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $5 | Strong Buy | Maintains | $5 | +669.23% | Dec 1, 2025 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $21 → $19 | Strong Buy | Maintains | $21 → $19 | +2,823.08% | Nov 21, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $5 | Strong Buy | Maintains | $5 | +669.23% | Nov 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3 → $2 | Strong Buy | Maintains | $3 → $2 | +207.69% | Nov 3, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $5 | Strong Buy | Maintains | $5 | +669.23% | Oct 31, 2025 |
Financial Forecast
Revenue This Year
7.47M
from 5.82M
Increased by 28.21%
Revenue Next Year
7.27M
from 7.47M
Decreased by -2.71%
EPS This Year
-0.18
from -2.34
EPS Next Year
-0.15
from -0.18
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 9.9M | 12.7M | ||||
| Avg | 7.5M | 7.3M | ||||
| Low | 5.1M | 3.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 69.4% | 70.3% | ||||
| Avg | 28.2% | -2.7% | ||||
| Low | -11.8% | -47.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.11 | -0.15 | ||||
| Avg | -0.18 | -0.15 | ||||
| Low | -0.29 | -0.15 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.